Skip to content

Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication

Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01277354
Enrollment
2
Registered
2011-01-14
Start date
2010-04-30
Completion date
2011-06-30
Last updated
2017-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression, Post-traumatic Stress Disorder, Stress Disorders

Keywords

Cognitive Processing Therapy (CPT)

Brief summary

The purpose of this study is to examine the effects of experiencing a previous pregnancy loss or complication on current physiological and emotional aspects of a current pregnancy.

Detailed description

This study will assess the effectiveness of cognitive processing therapy (CPT) or cognitive behavioral therapy (CBT) among women who are experiencing symptoms of post-traumatic stress disorder (PTSD) and/or anxiety relating to a previous pregnancy loss or complication. Lastly, this study includes an option to participate in a procedure whereas startle response will be measured using the eyeblink reflex twice during pregnancy and once in the postpartum period. Startle response is examined using a standard acoustic startle procedure whereby heart rate, skin temperature and eye blinking reflex are measured.

Interventions

BEHAVIORALCognitive Processing Therapy

CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others.

BEHAVIORALWaitlist Placebo

Behavioral ratings are conducted by a blind rater.

Sponsors

March of Dimes
CollaboratorOTHER
University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

* Meet DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for full PTSD or partial PTSD. * Clinician Administered PTSD Scale (CAPS) score of ≥18. * Gestational age at the time of presentation is between 8 and 30 weeks. * History of at least one of the following: previous pregnancy loss or losses, voluntary termination due to fetal anomaly, obstetrical complication including childbirth, premature birth (\<32 weeks), unexpected neonatal complication, emergency C-section, neonatal death within 28 days of delivery. * Fluency in spoken and written English.

Exclusion criteria

* Presence of any lifetime or comorbid DSM-IV Axis I psychotic disorder (including bipolar disorder and MDD (Major Depressive Disorder) with psychotic features and excepting Psychosis NOS (Not Otherwise Specified) related to sensory hallucinations, i.e. reexperiencing symptoms). * Presence of any comorbid Axis I or Axis II (as determined using the SCID-II (Structured Clinical Interview for DSM-IV)) disorder, which would require immediate treatment or renders the subject clinically unsuitable for this RTC (randomized clinical trial). * History of PTSD due to a NON-Pregnancy related traumatic event. * Presence of a known abnormality in the present fetus. * Presence of a serious medical or neurological illness. * Starting a new psychotropic agent within the previous 3 months. * Assessed to require a new psychotropic medication at the screening appointment or an adjustment in current dose of psychotropic medication.

Design outcomes

Primary

MeasureTime frameDescription
CPT Effectiveness as Determined by the Number of Participants With CAPS Score Decrease of 50% From Baseline to Week 66 weeksThe CAPS will be used in the diagnosis of PTSD, assessment of the impact of symptoms on function, assessment of the severity of symptoms at baseline, and weekly throughout the study. The CAPS in this particular study must decrease by 50% for CPT to be deemed effective.

Countries

United States

Participant flow

Recruitment details

Recruitment for this project was slow and only two subjects matriculated during the period that this project was active.

Participants by arm

ArmCount
CPT Group
Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
1
Waitlist Group
Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
1
Total2

Baseline characteristics

CharacteristicTotalCPT GroupWaitlist Group
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
2 Participants1 Participants1 Participants
Region of Enrollment
United States
2 participants1 participants1 participants
Sex: Female, Male
Female
2 Participants1 Participants1 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 10 / 1
serious
Total, serious adverse events
0 / 10 / 1

Outcome results

Primary

CPT Effectiveness as Determined by the Number of Participants With CAPS Score Decrease of 50% From Baseline to Week 6

The CAPS will be used in the diagnosis of PTSD, assessment of the impact of symptoms on function, assessment of the severity of symptoms at baseline, and weekly throughout the study. The CAPS in this particular study must decrease by 50% for CPT to be deemed effective.

Time frame: 6 weeks

Population: Please note that there were only a total of 2 participants involved in this study. Funding was lost to continue and the study was terminated.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CPT GroupCPT Effectiveness as Determined by the Number of Participants With CAPS Score Decrease of 50% From Baseline to Week 61 Participants
Waitlist GroupCPT Effectiveness as Determined by the Number of Participants With CAPS Score Decrease of 50% From Baseline to Week 61 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026